For each clinical scenario, select the corresponding 2022 ACC/AHA/HFSA heart-failure stage.
Matrix
Choose your responses, then check the answer.
Explanation
Stage A means risk for heart failure without symptoms, structural heart disease, increased filling pressure, or biomarker evidence of myocardial injury. Stage B is pre-heart failure: the client has no current or prior symptoms but has structural disease, increased filling pressure, or persistently elevated natriuretic peptide or troponin. Stage C includes structural heart disease with current or previous heart-failure symptoms. Stage D is advanced heart failure with symptoms that interfere with daily life and recurrent decompensation despite optimized guideline-directed therapy. Treatment is not assigned by stage label alone: for example, ACE inhibitor and evidence-based beta-blocker recommendations in Stage B specifically apply to selected clients such as those with LVEF 40% or less, not every person with pre-HF.
Correct Answer Classify risk factors without structural or biomarker abnormality as Stage A, asymptomatic structural or biomarker evidence as Stage B pre-HF, current or prior symptoms as Stage C, and persistent advanced symptoms despite optimized therapy as Stage D.
Why It Fits The stages describe progression from risk to objective pre-HF, symptomatic disease, and advanced refractory disease. Symptoms separate Stage B from Stage C, while failure of optimized therapy and recurrent severe limitation identify Stage D.
Clinical Picture Think of four doors: risk only, objective change without symptoms, objective change with symptoms, and advanced symptoms despite treatment. A client does not move backward to an earlier stage when symptoms improve.
Memory Link A at risk, B before symptoms, C clinical symptoms, D difficult despite therapy.
NCLEX Rule Do not attach the full four-pillar HFrEF regimen to every Stage B client. Medication recommendations depend on phenotype and findings, such as LVEF 40% or less, prior myocardial infarction, kidney function, blood pressure, and contraindications.
Why the Alternatives Fail Hypertension alone without structural or biomarker evidence remains Stage A. Asymptomatic LV hypertrophy or reduced EF is Stage B. A history of symptoms places structural heart disease in Stage C even when the client is currently compensated.
Source
12022 AHA/ACC/HFSA Heart Failure Guideline
The nurse is reviewing records in a cardiology clinic and must distinguish risk factors, pre-heart failure, symptomatic heart failure, and advanced heart failure before planning follow-up.
ARNI — Angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan); first-line in HFrEF.
SGLT2 inhibitor — Glifozin class with HF benefit independent of diabetes status.
MRA — Mineralocorticoid receptor antagonist (spironolactone, eplerenone) for HFrEF.